One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Journals package 3months
-
http://medilib.ir
- Duration of Time : 93 Day
- :
Price : 100$- Special Price : 50$
Rewriting Risk: A Data-Driven Look at Myeloma Genetics.
doi : 10.1200/JCO-25-00988
Volume 43(24) pgs. 2661-2758,e31-e58 August 20, 2025
Cancer Surveillance in the United States in Jeopardy: Leveraging 21st Century Technology to Enhance Public Health.
doi : 10.1200/JCO-25-00754
Lisocabtagene Maraleucel Versus Standard of Care for Second-Line Relapsed/Refractory Large B-Cell Lymphoma: 3-Year Follow-Up From the Randomized, Phase III TRANSFORM Study.
doi : 10.1200/JCO-25-00399
Co-Occurrence of Cytogenetic Abnormalities and High-Risk Disease in Newly Diagnosed and Relapsed/Refractory Multiple Myeloma.
doi : 10.1200/JCO-24-01253
Outcomes of Frontline Triplet Regimens With a Hypomethylating Agent, Venetoclax, and Isocitrate Dehydrogenase Inhibitor for Intensive Chemotherapy-Ineligible Patients With Isocitrate Dehydrogenase-Mutated AML.
doi : 10.1200/JCO-25-00640
Multisite Randomized Trial of Inpatient Palliative Care Intervention for Patients Undergoing Hematopoietic Stem Cell Transplantation.
doi : 10.1200/JCO-25-00378
Breastfeeding After Hormone Receptor-Positive Breast Cancer: Results From the POSITIVE Trial.
doi : 10.1200/JCO-24-02697
Camrelizumab Plus Famitinib versus Camrelizumab Alone and Investigator's Choice of Chemotherapy in Recurrent or Metastatic Cervical Cancer: A Randomized, Phase II Study.
doi : 10.1200/JCO-24-02495
International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma.
doi : 10.1200/JCO-24-01893
Inappropriate Conclusions on Surrogate End Points in Early Breast Cancer Trials.
doi : 10.1200/JCO-25-00325
Methodologic Considerations in Assessing Invasive Disease-Free Survival as a Surrogate End Point for Overall Survival in Trials for Early Breast Cancer.
doi : 10.1200/JCO-25-00502
Reply to: "Inappropriate Conclusions on Surrogate End Points in Early Breast Cancer Trials" and "Methodologic Considerations in Assessing Invasive Disease-Free Survival as a Surrogate End Point for Overall Survival in Trials for Early Breast Cancer".
doi : 10.1200/JCO-25-01041
Erratum: Hematopoietic Stem Cell Transplantation Outcomes for High-Risk AML: A Report From the Children's Oncology Group.
doi : 10.1200/JCO-25-01516
Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2025.1
doi : 10.1200/JCO-25-01061
Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2025.1
doi : 10.1200/JCO-25-01062
